RxDoctor Payments Data

Michael Semmler

Optometrist · Hot Springs Village, ARNPI 1679626675

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 28 payments — averaging $59.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$761
  • Coopervision Inc.$205
  • Topcon Healthcare, Inc.$146
  • Rxsight Inc$120
  • LKC Technologies, Inc.$115
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$77
  • plus $241 from 6 others

What the payments were for

  • Food & beverage$1,62297%
  • Entertainment$433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,665 in reported general payments places this provider in the 80th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$166,710
Medicare patients
1,022
Services billed
2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$23,828
LumiganBimatoprost42$22,658
Cyclosporine15$11,395
Latanoprost351$2,961
Fluorometholone39$2,590
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat105$2,256
Prednisolone Acetate50$1,553
Brimonidine Tartrate54$1,311
Timolol Maleate116$716
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha61$670
Doxycycline Hyclate75$575
Dorzolamide Hcl32$474
Clobetasol Propionate16$280
Ketorolac Tromethamine16$272
Dexamethasone Sodium Phosphate11$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$34$46,48571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Hot Springs Village

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →